Relmada Therapeutics (RLMD) Receivables - Other (2016 - 2023)
Relmada Therapeutics (RLMD) posted quarterly Receivables - Other of -$512432.0 for Q1 2023, down 200.0% quarter-over-quarter from $512432.0 in Q4 2022.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Receivables - Other (2016 - 2023) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Receivables - Other for 7 consecutive years, with -$512432.0 the latest figure, recorded in Q1 2023.
- In Q1 2023, Receivables - Other changed N/A year-over-year to -$512432.0; the TTM figure through Dec 2023 stood at -$512432.0 (down 200.0% YoY), while the FY2023 annual figure was -$512432.0, down 200.0% from the prior year.
- Receivables - Other declined to -$512432.0 in Q1 2023 per RLMD's latest filing, from $512432.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $512432.0 in Q4 2022 and bottomed at -$512432.0 in Q1 2023.
- Historically, Receivables - Other has averaged $9254.8 across 4 years, with a median of -$84725.5 in 2019.
- On a YoY basis, Receivables - Other climbed as much as 5177.14% in 2019 and fell as far as 2223.49% in 2019.
- Relmada Therapeutics' Receivables - Other stood at -$176980.0 in 2019, then surged by 104.25% to $7529.0 in 2020, then surged by 6706.11% to $512432.0 in 2022, then slumped by 200.0% to -$512432.0 in 2023.
- Business Quant data shows RLMD's Receivables - Other at -$512432.0 in Q1 2023, $512432.0 in Q4 2022, and $7529.0 in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | -512,432.00 |
| Dec 31, 2022 | 512,432.00 |
| Mar 31, 2022 | 3.61 Mn |
| Sep 30, 2021 | 1.61 Mn |
| Mar 31, 2020 | 7,529.00 |
| Dec 31, 2019 | -176,980.00 |
| Sep 30, 2019 | -176,980.00 |
| Jun 30, 2019 | 177,000.00 |
| Dec 31, 2018 | 169,363.00 |
| Sep 30, 2018 | -7,617.00 |
| Jun 30, 2018 | 7,617.00 |
| Dec 31, 2017 | -150,617.00 |
| Sep 30, 2017 | 150,617.00 |
| Jun 30, 2017 | 232,597.00 |
| Dec 31, 2016 | 2,350.00 |
| Sep 30, 2016 | 2,350.00 |
| Jun 30, 2016 | 231,942.00 |